SCNN1A抗体;SCNN1A Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P11560(SCNN1A Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P11560(SCNN1A Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The SCNN1A antibody targets the α-subunit of the epithelial sodium channel (ENaC), encoded by the *SCNN1A* gene. ENaC, a heterotrimeric protein composed of α, β, and γ subunits, regulates sodium reabsorption in epithelial tissues, notably in the kidneys, lungs, and colon. The α-subunit (SCNN1A) is essential for channel assembly and function, influencing fluid homeostasis, blood pressure regulation, and airway surface liquid balance. Dysregulation of ENaC activity is linked to pathologies such as hypertension, pulmonary edema, Liddle syndrome (a hereditary form of hypertension), and cystic fibrosis-related sodium hyperabsorption.

SCNN1A antibodies are widely used in research to study ENaC expression, localization, and functional modulation under physiological or disease conditions. They enable detection of SCNN1A via techniques like Western blotting, immunohistochemistry, and immunofluorescence, aiding in investigations of ENaC trafficking, post-translational modifications (e.g., proteolytic cleavage), and interactions with regulatory proteins (e.g., aldosterone or proteases). These antibodies also support clinical research into ENaC-targeted therapies, such as inhibitors for cystic fibrosis or hypertension. Validating antibody specificity is critical due to structural similarities among ENaC subunits and potential cross-reactivity.